What is Winstrol (Stanozolol)?

Winstrol is the brand name for stanozolol, a synthetic anabolic-androgenic steroid derived from DHT. Unlike most AAS, stanozolol is available in both oral and injectable forms. It was FDA-approved for hereditary angioedema and anemia. It does not aromatize but causes joint dryness and is hepatotoxic in the oral form.

Why does Winstrol cause joint pain?

Stanozolol reduces synovial fluid production in joints by inhibiting hyaluronic acid synthesis. This leads to decreased joint lubrication and the characteristic 'joint dryness' or 'crackling joints' associated with Winstrol use. This effect is typically reversible upon discontinuation but can be significant in athletes performing heavy compound movements.

Does Winstrol aromatize?

No. Stanozolol cannot be aromatized to estrogen. It produces dry, hard gains without water retention or gynecomastia risk. However, this also means it provides no estrogen-mediated protective effects on joints or cardiovascular health.

Is injectable Winstrol safer than oral?

For the liver, yes — injectable stanozolol bypasses first-pass hepatic metabolism and causes less direct hepatotoxicity. However, injectable Winstrol is water-based and known for painful injections. Both forms still suppress HPTA, have similar androgenic effects, and both still carry some hepatotoxic risk (particularly at high doses).

Anabolic Steroid • Oral / Injectable • Schedule III

Winstrol: The Cutting Standard — Educational Reference

By Steve B, HighPeptides Editor

Last updated: March 2026

Stanozolol (Winstrol) has the unusual distinction of being FDA-approved — for hereditary angioedema and aplastic anemia — while remaining one of the most recognized cutting AAS. Available in oral and injectable forms, non-aromatizing, and notorious for joint dryness. This reference covers its pharmacology, documented effects, hepatotoxicity, and harm reduction context.

320:30

Anabolic:Androgenic Ratio
(vs testosterone = 100:100)

25–50mg

Reported Oral Daily Dose
or 50mg injectable EOD

9 hrs (oral)
24 hrs (inj)

Half-Life by Form
Detection: 3 weeks – 2 months

📋 On this page

How Stanozolol Works
What the Research Shows
Side Effects & Risks
Key Takeaways
🛒 Liver, Joint & Cardiovascular Support
Related Resources

Mechanism of Action

How Stanozolol Works

Stanozolol is a heterocyclic AAS — it has a pyrazole ring fused to the A-ring of the steroid nucleus, making it unique in structure among AAS. This pyrazole modification prevents aromatization and confers unusually high anabolic:androgenic selectivity.

🔬

Pyrazole Ring — Non-Aromatizing Structure

The fused pyrazole ring at C-3/4 of the A-ring completely prevents aromatase-mediated conversion to estradiol. This gives stanozolol a unique pharmacological profile among AAS: high anabolic potency with no estrogenic activity. Users experience dry, hard gains — no water retention, no gynecomastia risk from the compound itself.

🦴

Joint Dryness — Synovial Fluid Reduction

Stanozolol inhibits hyaluronic acid synthesis in synovial tissue, reducing the viscosity and quantity of synovial (joint) fluid. This produces the characteristic "drying out" of joints that bodybuilders describe — reduced cushioning, often leading to joint pain, crackling, and increased injury risk during heavy lifting. This effect is typically reversible upon discontinuation.

🩸

C1-Inhibitor Enhancement — Angioedema Mechanism

Stanozolol's FDA-approved indication — hereditary angioedema — is mediated through increased hepatic synthesis of C1-inhibitor protein. Patients with HAE have deficient C1-inhibitor, causing recurrent swelling attacks. Stanozolol (Winstrol, Winzomol) raises C1-inhibitor levels by 50–100%, dramatically reducing attack frequency. This clinical use demonstrates real therapeutic value independent of anabolic effects.

💊

Oral vs Injectable — Different Hepatic Profiles

Oral stanozolol is 17α-alkylated and hepatotoxic. Injectable stanozolol (an aqueous suspension) bypasses first-pass metabolism and is significantly less hepatotoxic per milligram — though injectable Winstrol is notorious for painful injections due to its water-based, crystalline particle suspension. Both forms cause similar anabolic and androgenic effects; the liver safety difference is the primary distinction.

Research Data

What the Research Shows

Data from FDA-approved clinical trials (HAE, aplastic anemia) and pharmacological studies on stanozolol.

HAE Attack Reduction (FDA-approved dose)

Clinical trial data — reduction in angioedema episodes

~50–80% reduction

Estrogenic Activity

Cannot aromatize — zero direct estrogen conversion

Zero

Hepatotoxicity (oral form)

17α-alkylated — significant ALT/AST elevation at typical doses

HIGH — 3–8× ULN

HDL Suppression

Marked HDL reduction — among worst of all AAS for lipid profile

40–70% HDL reduction

HPTA Suppression

Moderate — similar to other AAS at equivalent doses

MODERATE–HIGH

Safety Profile

Side Effects & Risks

Hepatotoxicity (oral form)

Limit oral cycle to 4–6 weeks, monitor liver enzymes

HIGH

Joint Pain / Injury Risk

Synovial fluid reduction — significant risk in heavy lifting athletes

HIGH in athletes

Cardiovascular Risk (lipids)

Severe HDL suppression — among worst AAS for cardiovascular profile

HIGH

Androgenic Effects (acne, hair loss)

Low androgenic rating but real androgenic effects reported

MODERATE

Bottom Line

Key Takeaways

✅ What We Know

FDA-approved for hereditary angioedema (increases C1-inhibitor)
Anabolic:androgenic ratio 320:30 — high anabolic selectivity
Cannot aromatize — zero estrogenic side effects
Available oral (hepatotoxic, 9hr half-life) and injectable (less hepatotoxic, 24hr)
Reduces synovial fluid — significant joint pain risk in athletes
Among worst AAS for HDL cholesterol — cardiovascular risk
HPTA suppression — PCT required post-cycle

⚠️ What We Don't Know

Whether joint protection supplements adequately mitigate synovial effects
Long-term cardiovascular outcomes at bodybuilding doses
Precise hepatotoxic threshold — individual variation is significant
Whether injectable form is truly safe enough for liver at high doses
Long-term HPTA recovery outcomes after prolonged stanozolol use

Harm Reduction Supplies

🛒 Liver, Joint & Cardiovascular Support

Winstrol's combination of hepatotoxicity (oral), joint dryness, and severe lipid effects requires multi-system monitoring.

🫁 TUDCAPrimary liver support for oral stanozolol hepatotoxicity 🧪 NACGlutathione precursor — hepatoprotective 🦴 Joint Support (Glucosamine)Partially mitigate Winstrol's joint-drying effects ❤️ Lipid Panel TestMonitor HDL — critical with stanozolol's lipid impact

Keep Reading

⚖️

Anavar Guide

Milder non-aromatizing oral AAS — less joint impact

→ 🔄

PCT Guide

Post-cycle therapy after oral AAS

→ 💉

Masteron Guide

Injectable non-aromatizing AAS — no joint dryness

→ 🧬

Turinabol Guide

Non-aromatizing oral AAS — no joint effects

→ 🩸

Testosterone Bloodwork

Essential labs for monitoring AAS use

→ 💪

Testosterone Guide

Commonly stacked with Winstrol

→

📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.

Get the Guide →

⚠️ Legal & Medical Disclaimer

This page is for educational and harm reduction purposes only. It is not medical advice. Stanozolol (Winstrol) is a Schedule III controlled substance in the United States. While it holds FDA approval for hereditary angioedema at therapeutic doses, non-medical use is illegal. It is banned by WADA and all major sports organizations. Use at bodybuilding doses carries significant health risks including hepatotoxicity, cardiovascular disease (severe HDL suppression), joint injury, and HPTA suppression. HighPeptides does not endorse or encourage the use of controlled substances. Consult a qualified physician before any decisions regarding hormone use.